In this study, the pan-PIM, PI3K and mTOR inhibitor, IBL-302, demonstrated efficacy across 40 breast cancer cell lines with GI50s ranging from 36 nM (MDA-MB-361) to 2656 nM (BT-483). This evidence concerns the gene MTOR and breast carcinoma.